The PCV works by introducing small amounts of inactivated bacterial antigens conjugated to a protein carrier. This stimulates the immune system to recognize and respond to these antigens without causing disease. When the vaccinated individual later encounters the actual pathogen, their immune system is primed to respond more effectively. In histological terms, this involves the activation of B lymphocytes and T lymphocytes, key players in the adaptive immune response, leading to the production of specific antibodies.
